2002
Gynecomastia is a real danger with some of these steroids, and some men even experience lactating nipples.
The recommended frequency of routine echocardiographic monitoring is every 6 to 12 months or as clinically indicated with the presence of signs and symptoms such as edema, new cardiac murmer, dyspnea or congestive heart failure.Cabergoline should be discontinued if an echocardiogram reveals new valvular regurgitation, valvular restriction or valve leaflet thickening.Cabergoline should be used with caution in patients exposed to other medications associated with valvulopathy.Postmarketing cases of pleural, pericardial and retroperitoneal fibrosis have been following administration of Cabergoline.
A common dosage for Cabergoline would be between .25mg and .50mg every 3.5 days.
What is Cabergoline (Cabaser)?
If you log out, you will be required to enter your username and password the next time you visit.
Most commonly, these are "preferred" (on formulary) brand drugs.
Late Dinner Affects Metabolism, May Lead to Weight Gain, DiabetesMetabolic Disease: Is It the Fat, Sugar, or Processed Food? Drug information provided by: IBM Micromedex Along with its needed effects, a medicine may cause some unwanted effects. Unfortunately, this anti-prolactin drug comes with its own set of side effects. In male rodents, the decrease in serum prolactin levels was associated with an increase in serum luteinizing hormone, which is thought to be a compensatory effect to maintain testicular steroid synthesis.
Patients receiving long term treatment with Cabergoline should undergo periodic assessment of their cardiac status and echocardiography should be considered.After a normal serum prolactin level has been maintained for 6 months, Cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with Cabergoline should be reinstituted. In addition to the adverse events that occurred in the patients with hyperprolactinemic disorders, the most common adverse events in patients with Parkinson's disease were dyskinesia, hallucinations, confusion, and peripheral edema. This drug is available at the lowest co-pay.
Although Cabergoline seems to be tolerated better than other DA's. Diseases & Conditions
Restoration of menses occurred in 77% of the women treated with Cabergoline, compared with 70% of those treated with bromocriptine.
2: This drug is available at a middle level co-pay.
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. 126702-overview
Since a possible dose-related effect was observed for nausea only, the four Cabergoline treatment groups have been combined.
Cabergoline Tablets, USP for oral administration, contains 0.5 mg of Cabergoline USP. This website also contains material copyrighted by 3rd parties.
Cabergoline might be cycled with steroids to avoid prolactin-related side effects.
In this study, the use of Cabergoline among persons with Parkinson's disease was associated with an increased risk of CVR when compared to non-ergot-derived dopamine agonists (DAs) and levodopa [Incidence Rate (IR) per 10,000 person years of 68.1 (95% confidence interval (CI): 37.2 - 115.3) for Cabergoline vs. 10.0 (95% CI: 5.2 - 19.4) for non-ergot DAs and 11.3 (95% CI: 7.2 - 17.0) for levodopa]. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient's serum prolactin level. Among patients with galactorrhea, this symptom disappeared in 73% of those treated with Cabergoline compared with 56% of those treated with bromocriptine.In hyperprolactinemic patients (n=51), the maximal prolactin decrease after a 0.6 mg single dose of Cabergoline was comparable to 2.5 mg bromocriptine; however, the duration of effect was markedly longer (14 days vs. 24 hours). Indicated for hyperprolactinemic disorders of either idiopathic or pituitary adenoma originMay increase by 0.25 mg q4Weeks (or longer) up to 1 mg 2x/weekImpulse control/compulsive behavior symptoms, including hypersexuality, increased libido and pathological gamblingHistory of pulmonary, pericardial, or retroperitoneal fibroti disordersHistory of cardiac valvular disorders as suggested by anatomical evidence of valvulopathy of any valve, determined by pretreatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosisInitial doses >1 mg may produce orthostatic hypotensionMay cause somnolence; avoid performing tasks that require mental alertnessMay cause orthostatic hypotension; avoid concurrent use with antihypertensivesImpulse control/compulsive behaviors reported in patients receiving therapy; this has been generally reversible upon reduction of dose or treatment discontinuation; prescribers should consider dose reduction or stopping medication if a patient develops such urges while receiving therapyLactation: excretion in milk unknown; not recommendedA: Generally acceptable.
Got something to say?